Molecular, immunological and structural characterization of mite allergens by Resch, Yvonne
 
 
 
 
 
 
 
 
 
 
 
DIPLOMARBEIT 
 
 
 
 
Titel der Diplomarbeit 
 
 
 
Molecular, immunological and structural characterization  
of mite allergens  
 
 
 
 
 
 
angestrebter akademischer Grad 
 
Magistra der Naturwissenschaften (Mag. rer.nat.) 
 
 
 
 
 
 
Verfasserin: Yvonne Resch 
Matrikel-Nummer: 0204269 
Studienrichtung /Studienzweig 
(lt. Studienblatt): 
A441 Diplomstudium Genetik - Mikrobiologie 
Betreuerin: Dr. Susanne Vrtala 
 
 
 
Wien, im  
 
 
 
März 2010 
  II
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The studies presented in this diploma thesis were conducted at the Department of 
Pathophysiology at the Medical University of Vienna under the supervision of Univ. 
Doz. Dr. Susanne Vrtala and Univ. Prof. Dr. Rudolf Valenta from March 2008 to 
March 2010.  
  III
 
 
 
 
 
 
 
 
 
 
 
An dieser Stelle möchte ich mich bei allen bedanken, die durch ihre fachliche und 
persönliche Unterstützung zum Gelingen der vorliegenden Diplomarbeit beigetragen 
haben.  
Zunächst möchte ich Herrn Univ. Prof. Dr. Rudolf Valenta dafür danken, dass er es 
mir ermöglicht hat, meine Diplomarbeit in seiner Arbeitsgruppe anzufertigen.  
Ein besonderer Dank gilt meiner Betreuerin Univ. Doz. Dr. Susanne Vrtala, die vom 
ersten Tag an stets ein offenes Ohr für Fragen und Probleme hatte und mir zu jeder 
Zeit mit fachlichem Rat zur Seite stand.   
Weiters bedanken möchte ich mich bei allen Mitarbeitern der Arbeitsgruppe 
Immunpathologie für die immer freundliche und hilfsbereite Unterstützung und vor 
allem das hervorragende Arbeitsklima.  
Ganz besonderer Dank gilt meiner Familie und meinem Freund Christoph, für die 
Liebe und das Verständnis, das sie mir während des gesamten Studiums und vor 
allem während der Dauer der Diplomarbeit entgegen gebracht haben.  
  IV
Table of Contents 
I. Introduction......................................................................................................... 1 
1. The origin of the term "allergy" ..................................................................... 2 
2. Hypersensitivity ............................................................................................ 3 
3. Pathophysiology of Type I allergy................................................................. 6 
4. Diagnosis of Type I allergy ......................................................................... 11 
5. Mite allergy................................................................................................. 15 
6. Aims of the Diploma thesis ......................................................................... 25 
7. References................................................................................................. 26 
II. Manuscript 1 ..................................................................................................... 33 
III. Manuscript 2 ..................................................................................................... 64 
IV. Summary - Zusammenfassung......................................................................... 71 
V. Curriculum vitae................................................................................................ 76 
 
 
 
 
Introduction 
 1
 
 
 
 
 
I. Introduction 
Introduction 
 2
1. The origin of the term "allergy" 
It was in 1906, when the term "allergy" (from the 
Greek allos – "other" and ergon – "work") was first 
used by the Austrian paediatrician Clemens von 
Pirquet (Figure 1, (1)) in an article in the Munchener 
Medizinische Wochenschrift (2). The reason for this 
neologism was his attempt to have a general phrase 
for describing any immunological phenomenon in an 
organism where an external agent causes a state of 
"changed or altered reactivity" after one or more applications. His definition did not 
discriminate between agents that lead to harmful reactions in the organism (e.g. 
serum sickness or anaphylaxis) from those which result in immunity against them (1). 
Pirquet's very broad definition of "allergy" soon changed its meaning and is 
nowadays used in a restricted manner, namely as a “disease following a response by 
the immune system to an otherwise innocuous antigen” (3). 
Fig. 1 Clemens von Pirquet (1) 
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2. Hypersensitivity 
Hypersensitivity reactions, defined as reactions that are mediated by 
immunologic mechanisms leading to tissue damage, are grouped into four types by a 
classification system designed by Robin Coombs and Philip Gell in 1963 (4) (Figure 
2, (3)). 
 
 
2.1. Type I Hypersensitivity 
Type I hypersensitivity is also known as immediate-type hypersensitivity due to 
the fact that reactions usually occur 15 to 30 minutes after exposure to the antigen. 
The mechanism of reaction involves IgE antibodies, which are produced in response 
to certain antigens called allergens. IgE binds to the surface of mast cells and 
basophils, via the high-affinity receptor Fc?RI. Upon a subsequent exposure to the 
same allergen, the sensitized cells become activated when allergens induce cross-
Fig. 2  Summary of the characteristics of the four types of hypersensitivity (3) 
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linking of the Fc?RI bound IgE antibodies. As a result of this activation, the cells 
degranulate and release various inflammatory chemical mediators that cause 
symptoms such as allergic rhinitis, acute urticaria, asthma or systemic anaphylaxis. 
 
2.2. Type II Hypersensitivity 
Hypersensitivity reactions of this type are caused by IgG antibodies that are 
directed against cell-associated antigens, and consequently mediate cell destruction 
via complement activation or ADCC (antibody dependent cellular cytotoxicity). 
Antigens recognized in this way, can either be part of the patient's cells, causing 
autoimmune diseases (e.g. autoimmune haemolytic anemia) or they are foreign, as it 
is the case in incompatible blood transfusion reactions. In special cases, the 
antibodies recognize and bind to cell surface receptors involved in cell signaling, 
where they either act as an agonist (e.g. in chronic urticaria) or antagonist (e.g. in 
myasthenia gravis, a muscle-weakness disease). 
 
2.3. Type III Hypersensitivity 
Type III hypersensitivity reactions are mediated by soluble antigen-antibody 
(IgG) immune complexes that are formed in large amounts. These complexes are 
normally removed by macrophages in the spleen or liver, but if they are produced in 
excess amounts this clearing mechanism is inadequate, resulting in aggregation of 
especially small complexes in capillaries between the endothelial cells. The immune 
complexes then activate the classical complement system leading to vasodilatation. 
Proteins of the complement system and the immune complexes themselves attract 
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neutrophiles that discharge proteolytic enzymes, thereby promoting massive 
inflammation which leads to tissue damage. 
 
2.4. Type IV Hypersensitivity 
In contrast to the other three types of hypersensitivity (I – III) described before 
which are antibody mediated, the type IV hypersensitivity is triggered by antigen-
specific effector T-cells. This type of hypersensitivity is also called delayed-type 
hypersensitivity due to the fact that the reaction occurs usually not until 12-48 hours 
after exposure to the antigen. Similar to a response to an infectious pathogen, 
effector T-cells, that were primed by a previous exposure to the antigen migrate to 
the site where the antigen is present. There they become activated and produce TH1 
or TH2 specific chemokines and cytokines, which cause the activation of 
macrophages or eosinophils. The following inflammatory reaction causes skin 
reactions (swellings, erythema, induration and dermatitis) if TH1 cells are involved, or 
chronic asthma and chronic allergic rhinitis in a TH2-dominated response. 
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3. Pathophysiology of Type I allergy 
As already mentioned in chapter I.2.1, type I allergy is characterized by the 
formation of immunoglobulin E (IgE) antibodies against normally harmless 
environmental antigens, so-called allergens. Its time course can be sub-divided into 
different phases, which will be described in detail in the following chapters. 
 
3.1. Sensitization and memory  
The primary immune response to an allergen, which leads to the production of 
IgE, is called sensitization. Many factors are described in the literature, which can 
play a part in the triggering of this process. They can be classified as host and 
environmental factors. Host factors include the time of allergic sensitization, which is 
known to occur in the first few years after birth (5, 6). In addition to the age, genetic 
factors also contribute to the development of type I allergies (7-9). In atopic 
individuals, who have a higher disposition to develop a type I allergy, structural and 
promoter variants of some genes were found, which might be important in 
determining atopy. Examples are the genes coding for the ?-chain of Fc?RI or a 
genetic variant of the ?-subunit of the IL-4 receptor. In addition to host factors, 
several environmental factors have so far been discussed to play a role in the 
formation of an allergic reaction. The fact, for example, that the prevalence of allergic 
disorders has increased over the last hundred years especially in industrialized 
countries, is often explained by the “hygiene hypothesis” (10, 11). This states that the 
reduced bacterial and parasitic exposure in developed countries due to a higher 
hygiene status and the vaccination of the population, results in an imbalance of the 
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immune system. The inadequate stimulation of the TH1 fraction of the immune 
system give rise to an overactive TH2 part, which then causes IgE-reactivity to 
normally harmless antigens. Nevertheless, proof of the contrary can be given by the 
observation that allergies are a common problem in developing countries too (12). 
Other factors, such as diesel exhaust particles, can act as a carrier for the allergens 
and thereby have an adjuvant effect in boosting the sensitization (13). One of the 
most important environmental factors is the allergen itself. Allergens have some 
characteristic properties, but it cannot be predicted whether an antigen acts as an 
allergen. It is known that almost all allergens are proteins or glycoproteins, that they 
are small in size (5 – 80 kDa) (14), are highly soluble, stable and are typically 
presented to the immune system at very low doses. 
After describing the factors that may influence the development of an allergen-
specific IgE response, a schematic representation of the course of sensitization and 
the formation of memory is shown in Figure 3 (15). 
 
 
 
 
Fig. 3 Overview of the allergen-specific immune response during sensitization and memory (15) 
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Production of IgE antibodies requires the differentiation of naïve T-cells into TH2 
cells, which then stimulate B-cells to switch the antibody isotype from IgM to IgE. The 
intrinsic properties of the allergen, the dose, the route of allergen presentation as well 
as certain cytokines are important factors that determine the fate of naïve CD4+ cells 
to differentiate into TH2 cells. Allergens are often delivered at low doses via the 
mucosa of the respiratory and gastrointestinal tract or through the epidermis of the 
skin. These sites of entry are also used by parasites to enter the body. As it is often 
claimed that the physiological function of IgE is to fight helminthic parasitic infections, 
cells of the immune system at these sites are specialized to produce cytokines that 
result in TH2 responses (3). In summary, the microenvironment of the allergen entry 
sites favours the development of TH2 cells (16). Allergens that enter the body are 
phagocytosed by antigen presenting cells, mainly myeloid dendritic cells, which then 
migrate to regional lymph nodes, where they present epitopes of the allergens to 
naïve T-cells using MHC. Once activated, the T-cells start to proliferate and to mature 
into effector TH2 cells. As such, they produce interleukin-4 (IL-4) and IL-13, which 
favour the immunoglobulin-class switching of specific B-cells to IgE. Alternatively,  
B-cells may uptake allergens via their membrane-bound immunoglobulins and 
directly present them to T-cells. 
Sensitization causes the production of allergen-specific IgE antibodies in allergic 
patients. Some of the allergen-specific lymphocytes form memory T- and B-cells that 
survive in an inactive state for a long period of time until they face the same allergen 
again and become reactivated (6, 17). 
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3.2. The immediate reaction 
IgE is captured by the high-affinity Fc? receptor (Fc?RI) (18), which is found on 
mast cells and basophils that reside in tissues. They become activated when 
allergens cross-link the receptors via binding to the IgE 
molecules. It is therefore necessary for allergens to have 
at least two epitopes for IgE binding. This cross-linking 
event leads to the induction of a signal cascade which 
leads to in the release of inflammatory mediators, such 
as enzymes (e.g. tryptase, chymase) and toxic mediators 
(e.g. histamine, heparin) by degranulation (Figure 4, 
(15)). The mediators cause an immediate increase in 
local blood flow and vessel permeability as well as tissue 
destruction. The clinical effects can be seen within minutes and are localized at the 
site at which mast cell degranulation occurs. Inhaled allergens cause allergic rhinitis, 
conjunctivitis and asthma, whereas food allergens provoke symptoms such as 
diarrhea and vomiting. 
IgE not only cross-links Fc?RI receptors, but also upregulates the expression of 
Fc?RI (19-22), and promotes the survival of mast cells by preventing apoptosis (23, 
24). 
 
3.3. The late-phase reaction 
Activated mast cells also synthesize and release cytokines (e.g. IL-4, IL-13, 
TNF-?), chemokines and lipid mediators (e.g. leukotrienes, platelet-activating factor). 
These recruit other leukocytes, including eosinophils and TH2 lymphocytes, to the site 
Fig. 4 Events of the 
immediate reaction (15) 
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of inflammation. 
After T-cells be-
come activated by 
IgE-facilitated and 
non-IgE facilitated 
presentation of 
allergen by antigen-
presenting cells, 
they proliferate and release pro-inflammatory cytokines such as IL-4, IL-5 and IL-13 
(Figure 5, (15)). IL-5 is a key mediator in eosinophil activation, which causes the 
release of highly toxic granule proteins and free radicals from these cells, resulting in 
significant tissue damage. In addition, activated eosinophils synthesize chemical 
mediators, which activate epithelial cells. This leads to a recruitment and activation of 
more eosinophils and leukocytes. Clinical manifestations, such as oedema, pain, 
warmth and erythema can be seen two or more hours after allergen contact. The 
late-phase reaction can develop into chronic inflammation, which is characterized by 
the permanent presence of effector T-cells and eosinophils in the injured tissue (e.g. 
chronic allergic asthma). 
Fig. 5 The late phase of an allergic reaction (15) 
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4. Diagnosis of Type I allergy  
Symptoms typical for an allergic disease such as rhinitis, redness and itching of 
the conjunctiva, sneezing and eczema often is a first evidence that a person is 
suffering from allergies. Nevertheless, further investigations, such as the medical 
history of the person, a physical examination as well as in vivo and in vitro tests are 
needed to confirm the diagnosis of an allergic disease. 
Allergy can be diagnosed in relation to the different aspects of the allergic 
reaction, which is indicated by the various arrows shown in Figure 6 (25). Those 
framed with red boxes will be described in further detail. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 Tools for diagnosing an IgE-mediated allergy (25) 
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4.1. Extract-based diagnosis 
After suggesting an allergy according to the medical history, sensitization to one 
or more allergen sources is usually confirmed by skin tests, which measure the 
allergic reaction in the skin. This technique is used since 1880 (26). The skin prick 
test is commonly performed on the forearm, where one drop of each allergen extract 
is placed on the skin and then a small prick is made with a lancet through the drop. A 
positive reaction, seen as a wheal and flare response, can be detected 10-15 min 
after exposure. Skin prick testing is the most often used technique for diagnosing 
allergy in patients as it is easy, quick to perform and cheap. Nevertheless, sometimes 
alternative diagnostic techniques must be used instead of the skin testing, for 
example if the patient is taking anti-histamines or if the skin is in such a bad condition 
that an interpretation of the skin test is very difficult. 
While skin tests determine the skin reaction to different allergen sources, in vitro 
assays such as the radioallergosorbent (RAST) test measure the amount of IgE in 
the patient's serum directed against an allergen extract. The extract, immobilized to 
solid phase, is incubated with the serum and allergen specific IgE antibodies that 
bind to the components of the extract, are then detected with a labelled anti human 
IgE antibody. The amount of the allergen extract specific IgE is expressed as 
kilounits antigen per liter (kUA/L) with one unit representing 2.4 ng of IgE, and scored 
on a scale from 0 (< 0.35 kUA/L) to 6 (> 100.00 kUA/L ) (Phadia). 
Introduction 
 13
4.2. Component-resolved diagnosis 
Both, the skin prick tests and the RAST assays are today performed with 
allergen extracts that are prepared from natural allergen sources using aqueous 
extraction (27). Although various methods have been developed in order to 
standardize these extracts, they show a great variability in the quantity of the different 
allergens (28, 29). In addition, contamination of the extracts with endotoxin or 
allergens from other allergen sources have been reported (30, 31). 
These problems can be overcome if pure and defined allergens, in the form of 
recombinant allergens, were used which are produced since the late 1980s. While 
allergen extracts only allow to determine the allergen source against which a patient 
is sensitized, diagnosis with recombinant allergens reveals the patient's exact IgE 
reactivity profile against the disease-eliciting allergens (32). Valenta et al. started to 
test allergic patients with recombinant allergens in the early 1990s (33, 34) and in 
1999 created the term "component-resolved diagnosis" (CRD) for the concept of 
using recombinant allergens for the diagnosis of type I allergy (32). Various studies 
have confirmed that recombinant allergens are a good alternative to allergen extracts 
for in vitro and in vivo diagnosis (reviewed in (35)). It has also been shown, that for 
most allergen sources a small number of recombinant allergens is sufficient for 
diagnosis of an allergy. Only four timothy grass pollen allergens (Phl p 1, Phl p 2, Phl 
p 5 and profilin) are necessary to diagnose grass pollen allergic patients (34, 36, 37). 
For house dust mite allergy, it has been shown that Der p 1 and Der p 2, the two 
major allergens, are sufficient to diagnose 97% of D. pteronyssinus allergic patients. 
Addition of Der p 5 and Der p 7 increased the percentage to almost 100% (38). 
Diagnosis with recombinant allergens also allows differentiation between co-and 
cross-sensitization. Several "species-specific" and cross-reactive marker allergens 
Introduction 
 14
have so far been identified (reviewed in (39), (40)). Examples for the former markers 
are the group 1, 2, 5 and 6 allergens of grass pollen, which is their exclusive source 
(41). Cross-reactive allergens are for example the tropomyosin Der p 10 from house 
dust mites, or profilin. The IgE reactivity of the patients against these marker 
allergens can give useful information about the sensitizing allergen source and 
whether an extract-based form of immunotherapy is advisable or not. 
Since the end of the 1980s, when the first allergen was produced in 
recombinant form (42), a large collection of recombinant allergens from the most 
important sources became available that display the immunological properties of their 
natural counterparts. To test IgE-reactivity to the large panel of allergens, a new type 
of in vitro test, the so-called “Immuno Solid-phase Allergen Chip” (ISAC), was 
developed by Hiller et al. (43). In this multi-allergen test system, recombinant 
allergens are printed as microarrays in triplets on glass slides. It currently enables the 
determination of a patient’s IgE reactivity profile against 103 individual allergens in a 
single step using only 20 µl of serum. Further diagnostic in vivo tests such as 
provocation tests, are necessary to confirm the clinical relevance of the IgE 
reactivities. 
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5. Mite allergy 
5.1. The history of the discovery of mite allergy 
It was in the early 1920s, when house dust was discovered as a cause of 
allergic disease in the context of asthma by Kern (44) and Cooke (45). In 1928, 
Dekker suggested that asthma is caused by allergens produced by mites in the 
house, but this study received only little attention (46). In 1967, Voorhorst et al. 
showed that there is a strong relationship between the allergenic potency of dust 
samples and the number of mites in dust samples and suggested mites of the genus 
Dermatophagoides to be the main source of allergens in house dust (47). Many 
subsequent investigations confirmed these findings. 
 
5.2. Description and life cycle of mites 
House dust mites of the species Dermato-
phagoides are globular in shape and have a 
creamy white colour. Due to their small size they 
can only be seen under the microscope (Figure 
7). The typical house dust mite is 420 µm long, 
while the width depends on the sex (245 µm for 
males, 320 µm for females). The body of the house dust mite also contains a striated 
cuticle. 
The life cycle of D. pteronyssinus and D. farinae consists of five stages: egg, 
larva, protonymph, tritonymph and adult. The completion of their life cycle takes 
Fig. 7 D. pteronyssinus
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about a month with the adult living an additional one to three months. During this 
time, the female mite lays about 60 to 100 eggs and produces about 2000 faecal 
particles, which are of great importance, as it is known that mite allergens are mainly 
present in the faeces.  
The house dust mite is named after its habitat, the household dust. One of the 
main components of dust are shed skin flakes, which are their preferred food source. 
One of the major limiting factors for mite survival is the relatively high required 
humidity (60-90%) (48). This is the reason why the mite content in the house dust is 
higher in spring than in winter, where the heating dries out the houses and reduces 
the air moisture. 
 
5.3. Allergenic mites species and their distribution 
Among the over 50 000 known species of mites, allergens, which lead to mite 
allergy have been described from the families Acaridae, Glycophagidae and 
Pyroglyphidae (49, 50), all belonging to the order Acariformes (Figure 8), subclass 
Acari, class Arachnida and phylum Arthropoda. 
 
 
 
 
 
 
 
 
Fig. 8 Phylogenetic relationships of the order Acariformes 
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Species of the family Acaridae (T. putrescentiae) are a minor source of mite 
allergens. The main species of the family Glycyphagidae are L. destructor,  
G. domesticus and B. tropicalis, also known as storage mites. Except for B. tropicalis, 
which is the prominent mite in tropical and subtropical regions (51), they play a less 
important role in mite allergy. 
The most important elicitors of mite allergy are the house dust mites (HDM) 
Dermatophagoides pteronyssinus, Dermatophagoides farinae and to much lesser 
extent Euroglyphus manyei, which all belong to the family Pyroglyphidae. The 
prevalence of these three major species of mites is dependent on the geographical 
region with D. pteronyssinus being the prevalent species in Europe, North and South 
America, Africa, Asia and Australasia (52). D. farinae is often misleadingly described 
as the American house dust mite, although it is dominant only in the north eastern 
regions of North America (53). D. farinae is predominately found in Sweden (54) and 
Poland (55), while the species distribution in most other countries is mixed (56). 
 
5.4. Allergens from mites  
Mite allergens are found in mite bodies, secreta and excreta with the faeces 
being the major source of house dust mite allergens (57). Der p 1, one of the two 
major house dust mite allergens, for example, becomes airborne almost exclusively 
on faecal particles (58). 
Mite allergens are arranged in groups according to their homologies and order 
of description. So far, 24 groups of mite allergens have been identified. Table 1 
(adapted from (59)) gives an overview of the biochemical function, the molecular 
weight as well as the IgE binding frequency of these allergens. Newly isolated 
allergens are given their official names by the World Health Organization and 
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International Union of Immunological Societies (WHO/IUIS) Subcommittee on 
Allergen Nomenclature and are listed at www.allergen.org. Nevertheless, several 
mite allergens have been described in the scientific literature that are not part of this 
list. These allergens can be found for example in the Allergome database 
(www.allergome.com). 
 
 
IgE binding* 
Group Biochemical function 
MW 
(kDa) 
SDS-
PAGE 
Der p Der f Eur m Lep d Gly d Blo t Tyr p 
1 Cysteine protease 25 64-100 78-90 ?     60-93 ? 
2 ML domain lipid binding protein 15 63-100 92-100 ? 59-78 94 7 56-72 
3 Trypsin 31 9-97 16 ?   ? 5-57 ? 
4 alpha-amylase 57 28-74 ? 0     6-62 ? 
5 Unknown 15 6-74 ?   9 ? 20-73 ? 
6 Chymotrypsin 25 41-65 41       11   
7 Unknown 26, 29, 31 13-57 46   62 ? ? ? 
8 Glutathione-S-transferase 26 9-96 ?   ? ? ?   
9 Serine protease 30 92 ?       ?   
10 Tropomyosin 37 6-55 25, 81 ? 13 ? 10-29 13 
11 Paramyosin 96 50, 75 50-82       52, 67   
12 Unknown 14           50   
13 Fatty acid binding protein 15 ? ?   13   11 6 
14 Large lipid transfer protein 177 ? 66, 84 ?     ?   
15 Chitinase 98, 105 70 70       ?   
16 Gelsolin 55   47           
17 EF hand binding protein 30   35           
18 Chitinase-like protein 60 63 54       ?   
19 Anti-microbial peptide 7           10   
20 Arginine kinase 40 15-44 ?     ? ?   
21 Unknown 15 56 ?       57, 93   
22 Unknown 17   ?           
23 Chitin-binding protein 14 61, 85**             
24 Troponin C 18             ? 
  allergens listed in the IUIS database  
  allergens additionally found in the Allergome database  
* binding frequency (% patients, variation due to different studies) 
** unpublished data    
? no IgE frequency data available    
Table 1. Characteristics of the 24 groups of mite allergens 
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A HDM protein is defined as an allergen when it binds IgE from more than 5% of 
sera from patients showing symptoms of a house dust mite allergy. The IgE binding 
frequencies that were described in different studies occasionally varied dramatically, 
not only between the species, but also within one species, as can be seen for groups 
3, 8 or 10 in Table 1. These varieties can be explained by the different number of 
tested patients, their selection as well as the geographic area, in which the IgE-
binding frequency was studied. Some of the allergens, initially designated as major 
allergens due to reports of IgE-binding frequencies of more than 50% (e.g. group 3 
and 10) (60, 61) are nowadays described as low-potency allergens (62). A 
classification of house dust mite allergens according to their IgE-binding activity was 
recently given by Thomas WR (unpublished data) and is summarized in Table 2. The 
latest discovered mite allergens are missing in this classification by Thomas and are 
therefore listed in a separate column. 
 
 
 
 
 
 
Due to the high IgE-binding frequency, the high amount of specific IgE directed 
to this allergen and their high content in mite extracts, group 1 allergens (together 
with group 2) are considered as the most important mite allergens. Therefore group 1 
allergens will be described in more detail in chapter I.5.6. Further information is also 
given about tropomyosin, the group 10 mite allergen, in chapter I.5.7., as it is subject 
of this diploma thesis. 
IgE binding activity allergens 
 Thomas WR new 
major 1, 2 23 
mid-potency 4, 5, 7, 21  
low 3, 6, 8, 9, 10, 13, 16, 17, 20 19 
uncertain 11, 14, 15, 18 22, 24 
Table 2. IgE binding activity of HDM allergens 
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5.5. Cross-reactivity of mite allergens 
Cross-reactivity in allergy is a phenomenon, where IgE antibodies originally 
produced against one specific allergen react with other allergens, which are 
sequentially or structurally similar and therefore share IgE-epitopes. 
Cross-reactivity among mite allergens is known with degrees varying from very 
low to very high dependent on the evolutionary relationship between the different 
mites. It was shown for example for group 2 allergens, that the cross-reactivity 
among the storage mites L. destructor, T. putrescentiae and G. domesticus was high, 
but only low between group 2 allergens from storage mites and Der p 2 from D. 
pteronyssinus (63). There is no IgE cross-reactivity of group 1 and 5 allergens 
between glycyphagid and pyrophagid mites (64, 65), which is consistent with their 
high sequence disparity of 65% (52). Tropomyosins, on the other hand, show a 
sequence identity of 95% among the order of Acariformes, which leads to extensive 
cross-reactions, also with tropomyosins from other arthropod species such as 
crustacean. They will be discussed in further detail in chapter I.5.7. and II. In 
summary one can state that mite allergens can be species-specific or cross-reactive. 
 
5.6. Group 1 allergens – cysteine proteases  
Der p 1 and Der f 1 are the most important allergens in this group. As indicated 
by the name, the group 1 allergens, or more precisely, Der p 1 was the first allergen 
described for house dust mites (1980) (66). It was also the first allergen of which the 
cDNA was isolated, cloned and sequenced (42). The group 1 allergens from  
D. farinae, E. marynei, B. tropicalis and T. putrescentiae have also been 
characterized some years later (1986, 1992, 2003 and 2006 respectively (67-69)). 
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Der p 1, Der f 1 and Eur m 1 show 85% sequence identity (52), whereas Blo t 1 is 
only 35% identical to the pyroglyphid group 1 allergens (69). 
Group 1 HDM allergens are cysteine proteases, belonging to the family of 
papain (CA1) which is widely distributed in plants and animals. They are produced in 
the gut of mites, where they act as digestive enzymes and get later incorporated into 
dung balls, each containing about 0.1 ng of the allergen (57). Because Der p 1 is 
found in such high concentrations in the house dust, its content in the dust is used as 
an index of environmental exposure to house dust mites (defined at the Third 
International Workshop on mite allergens and asthma 1997). 
Group 1 allergens are synthesized as enzymatically inactive pro-enzymes. Der 
p 1, being representative for this group, consists of an 18aa long signal peptide, a 
80aa long pro-peptide and the mature region comprises 222aa. The pro-peptide 
inhibits the activity of the enzyme as it occludes the active site. Activation of the 
protein occurs under acidic conditions, when the solvent accessibility of the pro-
peptide residues increases and therefore exposes the sequence to Der p 1, which 
then is able to cleave its own pro-sequence (70). 
The allergenic activity of Der p 1 somehow seems to be to be related to its 
protease activity, as Der p 1 negatively influences functions of the innate and 
adaptive immune system. Der p 1 increases the permeability of bronchial mucosa by 
cleaving components of the intercellular tight junctions such as occludin, and 
consequently facilitates access to antigen-presenting cells (71). Der p 1 cleaves 
CD23 which may increase the production of IgE (72, 73) whereas digestion of CD25, 
the IL-2 receptor, by Der p 1, may result in a bias toward a TH2 immune response 
(74). 
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5.6.1.1. Expression of recombinant group 1 allergens  
Attempts to produce Der p 1 as a recombinant active allergen have been made 
since its cDNA was cloned in 1988, when it was tried to express the mature Der p 1 
as a GST-fusion protein in E.coli. The protein, however, showed only a weak IgE-
binding activity (42). The probable reason for this weak IgE reactivity was that Der p 
1 was not expressed together with its pro-sequence. It is known for a lot of proteases, 
that the pro-sequence plays an important role in the correct folding of the molecules 
(75, 76). Therefore, Der p 1 was later expressed together with its pro-peptide, but this 
raised the problem of how to remove the additional amino acids after expression, to 
obtain the mature protein. It is published for papain, that the pro-sequence can be 
cleaved when incubated at 60°C for 15-30min at pH values between 3.7 and 4.2 (75). 
The literature shows that these conditions did not always lead to the activation of 
proDer p 1 (77, 78). Nevertheless, autocleavage of the propeptide worked when the 
protein was expressed in the yeast Pichia pastoris, but the mature protein showed a 
reduced IgE binding frequency (79). Because proteins expressed in yeast tend to be 
hyperglycosylated, the N-glycosylation motif was removed by the substitution of an 
asparagine residue to a glutamine residue. The resulting protein showed full 
enzymatic activity and IgE binding comparable to natural Der p 1 (80). 
Der f 1, which shows 80% homology to Der p 1, was expressed as proDer f 1 in  
E. coli and was then activated under acidic conditions. The mature protein had equal 
protease and IgE binding activities as nDer f 1 (81). Attempts to produce recombinant 
Der p 1 in the same way, however failed (unpublished data). 
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5.7. Group 10 allergens – tropomyosins 
Group 10 allergens belong to the family of tropomyosins, which together with 
troponin, actin and myosin play an important role in the Ca-dependent regulation of 
muscle contraction (82). The cDNA of tropomyosin encodes a 284 aa long poly-
peptide, which is folded in an ?-helical manner. Two of these proteins are wound 
around each other forming a coiled-coil structure (83). Being found in the skeletal 
muscle of the mites, it is not surprising that Der p 10 is the 23rd most abundant 
protein produced by the mite (84). 
The first allergen described for the group 10 allergens was Der f 10 from D. 
farinae in 1995 (61). In this initial report an IgE-binding frequency of 80.6% was 
described, which led to the assumption that Der f 10 was a major mite allergen. Der p 
10, however, which was cloned and expressed as recombinant protein three years 
later, bound IgE from only 5.6% of mite allergic patients (85). Low IgE-binding 
frequencies were also reported from the later identified group 10 allergens of 
glycyphagid mites, Lep d 10 (13%) and Blo t 10 (20-29%) as well as from Tyr p 10 
(12.5%) (86-88). 
The sequences of tropomyosin proteins are highly conserved among 
invertebrates. Der p 10 shares 91 – 96% identical amino acids with tropomyosins 
from storage mites (Tyr p 10, Gly d 10 and Lep d 10) and 80% with those of 
crustacean, while the sequence identity is only 50% to human tropomyosins (52). 
Being consistent with the conserved sequence of tropomyosins among invertebrates, 
IgE cross-reactivities of mite tropomyosins with tropomyosins from other arthropods 
such as cockroach and shrimp are reported (89, 90). Comparing the IgE-binding 
epitopes of the shrimp tropomyosin Pen a 1 with the homologous sequences from 
Der p 10 and Der f 10, revealed that four of the eight identified shrimp epitopes had 
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an identical amino acid sequence with the mite tropomyosins and two differed only in 
one amino acid (91). 
The high IgE binding frequencies of group 10 allergens obtained in Japan 
(80.6%) (61) and Africa (55%) (12) are probably the result of a regional cross-
reactivity, as studies in Europe (38), Korea (88) and Australia (62) showed low IgE 
binding frequencies for group 10 allergens. 
The IgE binding frequencies for group 10 allergens were all obtained using 
recombinant tropomyosin proteins except for the study of Aki et al. (61), where the 
native form of the protein was also used resulting in the very high IgE binding 
frequency of 80.6%. Nevertheless, almost the same frequency was also obtained 
with the recombinant protein in this study excluding the possibility that the 
recombinant proteins show reduced IgE binding compared to their natural 
counterparts. 
The recombinant tropomyosins were all expressed in E. coli, either as a 
Glutathione-S-transferase (GST) fusion protein as it is the case for Der p 10 (38), Der 
f 10 (61) and Blo t 10 (87), as a His tagged protein (Der p 10 (62), Tyr p 10 (88)) or in 
a non-fusion form (Der p 10 (85), Lep d 10 (86)). 
A major interest in group 10 allergens is attributed to the fact that tropomyosin 
proteins are the major allergens in species belonging to the subphylum crustacean 
(e.g. shrimp, lobster and crab) and phylum mollusca (e.g. squid, snail and mussel), 
all known to cause adverse food reactions in allergic individuals. The sequences of a 
lot of these allergenic tropomyosins have so far been identified, most of them were 
cloned and expressed as recombinant proteins such as Pen a 1 (shrimp) (92), Cha f 
1 (crab) (93) and Hom a 1 (lobster) (94). 
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6. Aims of the Diploma thesis 
The major aim of this thesis was to study the relevance of the house dust mite 
allergen Der p 10 in mite allergic patients. The allergen should be produced as a 
recombinant protein that equals its natural counterpart regarding biochemical and 
immunological properties. A cDNA encoding Der p 10 was obtained from D. 
pteronyssinus RNA by reverse transcription with specific primers and should be 
expressed as a non-fusion protein in E. coli. After purification to homogeneity, mass 
spectroscopy and circular dichroism (CD) analysis should confirm the correct size 
and folding of recombinant Der p 10. The IgE-binding frequency of the mite 
tropomyosin in an Austrian population should be tested with sera from over 1000 D. 
pteronyssinus allergic patients. The allergenic activity of rDer p 10 should be studied 
in an in vitro mediator release assay using rat basophil leukaemia (RBL) cells 
transfected with the human Fc?RI receptor, which are loaded with mite allergic 
patients' serum IgE before. 
In the second part of the Diploma thesis the existence of mite specific IgE 
antibodies in the serum of a patient who showed an allergic anaphylactic reaction to 
a traditional Chinese medicine (TCM) tea should be tested. 
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Abstract 
Background: The mite allergen Der p 10 cross-reacts with tropomyosins in seafood 
but has not been studied in detail in house dust mite (HDM) allergic patients. 
Objective: To express and purify a recombinant Der p 10 equivalent to natural Der p 
10 and to evaluate it in HDM allergic patients. 
Methods: rDer p 10 was expressed in E. coli, purified and characterized by mass 
spectrometry and circular dichroism. It was tested for IgE reactivity in 1322 HDM 
allergic patients. Detailed IgE-reactivity profiles to six HDM allergens (Der p 1, 2, 5, 7, 
10, 21) were established for a subgroup of Der p 10-positive and negative sera. The 
allergenic activity was evaluated in basophil degranulation experiments. 
Results: rDer p 10 is an ?-helical protein sharing IgE epitopes with nDer p 10. It is 
recognized by 15.2% of HDM-allergic patients. The majority of Der p 10-positive 
patients showed IgE reactivity to several other HDM allergens besides the major 
allergens (Der p 1, Der p 2) while some showed a rather selective Der p 10 reactivity. 
Der p 10-negative patients were primarily sensitized to Der p 1 and/or Der p 2. The 
allergenic activity of Der p 10 was high only in few patients with strong and selective 
IgE reactivity to Der p 10. 
Conclusion: Der p 10 may be a diagnostic marker for HDM allergic patients with 
additional sensitization to allergens other than Der p 1 and Der p 2 who may require 
attention when allergen-specific immunotherapy is considered. 
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Clinical implications: 
Diagnostic testing with Der p 10 may be used to identify patients who may be not 
suitable for immunotherapy with most of the currently available HDM-extracts.  
 
Capsule summary:  
We produced rDer p 10 equivalent to its natural counterpart that may be used as a 
diagnostic marker allergen to prescribe HDM-specific immunotherapy. 
 
Key words:  
House dust mite allergy, Der p 10, tropomyosin, recombinant allergens, serological 
diagnosis, allergenic activity, RBL assay, immunotherapy 
 
Abbreviations:  
HDM, house dust mite 
cDNA, complementary deoxyribonucleic acid 
RT-PCR, reverse transcription polymerase chain reaction 
SDS-PAGE, sodium dodecylsulfate-polyacrylamide gel electrophoresis 
MALDI-Tof, matrix-assisted laser desorption and ionization-time of flight mass 
spectrometry 
UV CD, ultraviolet circular dichroism 
BSA, bovine serum albumin 
RBL, rat basophil leukaemia 
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Introduction 
House dust mites, especially the species Dermatophagoides pteronyssinus and 
D. farinae, are a frequent cause of allergy worldwide with around 20% of the 
population and more than 50% of allergic patients being sensitized to them.1, 2 House 
dust mite allergens are among the most common triggers of asthma and allergic 
rhinitis.3, 4 The frequency of IgE recognition, allergenic activity and clinical relevance 
of the major HDM allergens, Der p 1 and Der p 2 has been well investigated.5-8 Both 
allergens are recognized by more than 90% of HDM allergic patients and are 
considered as the major HDM allergens.5 More than 20 other mite allergens have 
been identified but their importance for mite allergy has only partly been studied.9 
Among these allergens, Der p 10, a tropomyosin, has received attention because it 
occurs as cross-reactive allergen in invertebrates10 and in particular in sea food 
where it has been described as an important allergen responsible for severe systemic 
anaphylaxis.11 
Although the first cDNA coding for a HDM tropomyosin Der f 10 was isolated 
already in 1995,12 information regarding the prevalence of recognition and 
importance of HDM tropomyosins are rare or highly contradictory. In the initial study 
describing Der f 10 a prevalence of IgE recognition of 80.6% was reported whereas 
for Der p 10 much lower IgE-binding frequencies (5 – 18%) were described.5, 13, 14 
However, in an African population 55% of the tested mite allergic patients showed 
IgE reactivity to Der p 10.15  Since Der p 10 has not been studied well in a large 
population of HDM allergic patients we first expressed recombinant D. pteronyssinus 
tropomyosin as a biologically active recombinant non-fusion protein in E. coli which 
equals its natural counterpart. We then screened sera from more than 1300 HDM 
allergic patients for IgE reactivity to rDer p 10 and performed a detailed analysis of 
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the IgE reactivity profiles to various HDM allergens in subgroups of Der p 10-positive 
and Der p 10-negative patients. The allergenic activity of rDer p 10 was compared 
with that of clinically important and highly allergenic HDM allergens, Der p 1 and Der 
p 2 in basophil degranulation assays. Our results indicate that Der p 10-positive 
patients differ substantially from Der p 10-negative patients regarding their 
sensitization profiles to HDM allergens which has implications for specific 
immunotherapy treatment. 
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Materials and methods 
Patients' sera 
One thousand three hundred and twenty two sera were collected from persons 
living in or in the surrounding area of Vienna, Austria who had attended an allergy 
outdoor clinic. For these persons the diagnosis of house dust mite allergy could be 
established based on respiratory symptoms (i.e. rhinitis and/or asthma) of allergy at 
home, positive skin prick test-reactivity to D. pteronyssinus and/or presence of mite-
specific IgE antibodies as determined by ImmunoCAP (Phadia AB, Uppsala, 
Sweden) or IgE reactivity to nitrocellulose blotted D. pteronyssinus extract.14 IgE-
reactivity to dot-blotted Der p 10 was performed for sera from all 1322 mite allergic 
patients. An extensive assessment of IgE reactivities to purified HDM allergens nDer 
p 1, rDer p 2, rDer p 5, rDer p 10 and rDer p 21 was performed for those patients 
where serum volumes ? 200 µl were available (i.e. 39 rDer p 10-positive and 31 Der 
p 10-negative patients). 
 
Purified house dust mite allergens 
Natural Der p 1 was isolated by affinity chromatography.16 Recombinant Der p 2 
was expressed in E. coli with a C-terminal hexa-histidine tag using the pET17b 
expression system (Novagen, Madison, WI, USA) and purified by Ni-NTA agarose 
(Qiagen, Hilden, Germany).17 Recombinant Der p 5, Der p 7 and Der p 21 were 
expressed as non-fusion proteins in E. coli and purified to homogeneity by ion 
exchange and hydrophobic interaction chromatography.18, 19 
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Expression in E. coli and purification of recombinant Der p 10 
A cDNA coding for Der p 10 (data base #AF016278) was obtained by reverse 
transcription from D. pteronyssinus RNA by RT-PCR with a Platinum Tag Kit 
(Invitrogen, Carlsbad, California) and the following primers: forward 5'-
CGGGATCCCATATGGAGGCCATCAAAAAGAAAATGC-3' and reverse 5'-
CGGGATCCTTAATAACCAGTAAGTTCGGC-3', containing BamHI (bold letters) and 
NdeI (underlined) restriction sites (MWG, Ebersberg, Germany).  The PCR product 
was cut with BamHI and NdeI, gel-purified and subcloned into the NdeI and BamHI 
sites of pET17b vector (Novagen, EMD, Madison, WI, USA). Both DNA strands were 
sequenced (MWG). 
Recombinant Der p 10 was expressed in E. coli BL21 (DE3) (Stratagene) as 
described.18 After lysis of cells, the protein was found in the supernatant, which was 
dialyzed against 1 M (NH4)2SO4, 50 mM Na2HPO4 pH 7, 1 mM DTT and loaded onto 
a Phenyl-Sepharose fast-flow column (GE Healthcare Bio-Science AB, Uppsala, 
Sweden). Bound proteins were eluted by a 0% to 100% linear gradient to 50 mM 
Na2HPO4 pH 7, 1 mM DTT. Fractions containing rDer p 10 were pooled, dialyzed 
against 10 mM Na2HPO4 pH 7, 0.25 mM DTT, loaded onto a column prepacked with 
Bio-Gel HT Hydroxyapatite (BioRad, Hercules, Calif., USA) and eluted by 
continuously increasing the concentration of Na2HPO4 to 300 mM. Fractions 
containing more than 90% pure rDer p 10 were pooled, dialyzed against 5 mM 
Na2HPO4 pH 7 and stored at –20°C. The purity of the protein was determined by 
SDS-PAGE and Coomassie blue staining20, and its concentration was measured 
using the Micro BCA Assay Kit (Pierce, Rockford, Ill., USA). 
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Matrix-assisted laser desorption and ionization–time of flight (MALDI-Tof) mass 
spectrometry and CD (Circular dichroism) analysis of rDer p 10 
rDer p 10 was desalted and further purified via reversed phase-HPLC (HP 1050 
binary gradient; column, Nucleosil-100 RP-18 150 x 4 mm, 5 µm; solvent A, water, 
0.1% FTA; solvent B, acetonitrile, 0.1% FTA; gradient, 10% B to 90% B in 15 min; 
flow, 1 ml/min; detection, UV at 215 nm; injected volume, 10 µl). Laser desorption 
mass spectra were acquired in a linear mode with a time-of-flight Compact MALDI II 
instrument (Kratos, Manchester, U.K.; piCHEM, Research and Development, Graz, 
Austria). rDer p 10 was dissolved in 10% acetonitrile, 0.1% trifluoroacetic acid and ?-
cyano-4-hydroxycinnamic acid (dissolved in 60% acetonitrile, 0.1% trifluoroacetic 
acid) was used as a matrix. For sample preparation, a 1:1 mixture of protein and 
matrix solution was deposited onto the target and air-dried. 
Far UV CD spectra of rDer p 10 were collected on a Jasco J-810 
spectropolarimeter (Japan Spectroscopic Co., Tokyo, Japan) using a 1mm path 
length quartz cuvette at a protein concentration of 0.26 mg/ml. Spectra were 
measured from 260 to 180 nm, with 0.5 nm resolution at a scanning speed of 50 
nm/min and resulted from averaging of three scans. All measurements were 
performed in 10 mM Na2HPO4 pH 7. For the temperature scan, spectra of rDer p 10 
were recorded by gradually increasing the temperature (5°C steps) from 25°C to 
95°C with a heat rate of 1°C/min, and after cooling down to 25°C again. The final 
spectra were baseline corrected by subtracting the corresponding buffer spectrum. 
Results were expressed as the mean residue ellipticity [?] at a given wavelength. The 
secondary structure content of rDer p 10 was calculated using the secondary 
structure estimation program CDSSTR.21 
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Preparation of an aqueous whole body mite extract 
An aliquot of 0.3 g of purified Dermatophagoides pteronyssinus whole bodies 
(Allergon, Vällinge, Sweden) was homogenized in 5 ml H2O containing 1 mM 
benzamidine and 1 mM PMSF using an Ultra-Turrax T25 Basic disperser (IKA, 
Staufen, Germany). The homogenate was extracted for 2 h at 4°C and the unsoluble 
fraction was removed by centrifugation (20 min, 3220 g, 4°C). The protein 
concentration was determined in the extract with the Micro BCA Assay Kit (Pierce). 
Aliquots were stored at -20°C.  
 
IgE immunoblot inhibition assays 
For IgE inhibition experiments, 0.4 mg/cm of the aqueous D. pteronyssinus 
extract or 1.5 µg/cm of rDer p 10 were separated by 14% SDS-PAGE and blotted 
onto nitrocellulose (Schleicher & Schuell, Dassel, Germany). Sera from mite allergic 
patients with IgE reactivity to Der p 10 were diluted 1:10 in gold buffer [50 mM 
sodium phosphate pH 7.4 0.5% (v/v) Tween-20, 0.5% (w/v) BSA and 0.05% (w/v) 
sodium azide] and pre-incubated with 350 µg/ml of the aqueous D. pteronyssinus 
extract or 20 µg/ml rDer p 10 o/n at 4°C. The pre-incubated serum samples or, for 
control purposes, the untreated serum (diluted 1:10) were then exposed to the 
nitrocellulose-strips o/n at 4°C and bound IgE antibodies were detected with 125I-
labeled anti-human IgE antibodies (Demeditec Diagnostics, Kiel, Germany) and 
visualized by autoradiography (Kodak XOMAT film).22 
 
IgE reactivity to purified allergens in a non-denaturating RAST-based dot blot 
assay 
Two µl aliquots of natural and recombinant house dust mite allergens (nDer p 1, 
rDer p 2, rDer p 5, rDer p 7, rDer p 10 and rDer p 21)16-19 as well as BSA as control 
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protein (each 0.25 µg/µl) were dotted onto nitrocellulose membranes (Schleicher & 
Schuell). The membranes were blocked with gold buffer, twice for 5 min and once for 
30 min, and incubated with mite allergic patients' sera diluted 1:10 dilution in gold 
buffer o/n at 4°C. Bound IgE antibodies were detected as described for the inhibition 
experiments and visualized by autoradiography. A quantification of dot blot signals 
was achieved with the NIH ImageJ software (version 1.42; http://rsb.info.nih.gov/ij/). 
The scanned film was analysed after conversion into an 8-bit greyscale image, 
background correction and inversion of the image. Thus, pixel values ranged from 0 
(black) to 255 (white). After outlining the individual dots using the elliptical tool, the 
integrated density was calculated as a product of “area” value (area of selection in 
square pixels) and "mean grey value" (sum of the grey values of all the pixels in the 
selection divided by the number of pixels). An example of the dot’s integrated density 
is shown for patient A39 (see Fig. E1 in the Online Repository at www.jacionline.org). 
Three independent measurements were done and averaged for each dot. The 
individual dots were grouped into three categories (weak, middle and strong) 
according to their “integrated density” values and marked white, grey and black in 
Table E1 (see Online Repository at www.jacionline.org) for better visualization. 
 
Rat basophil leukemia cell mediator release assay 
The RBL (rat basophil leukaemia) cell-release assay was performed as 
described previously by Schulmeister et al.23 Briefly, human Fc?RI-transfected RBL 
cells (clone RBL-703/21)24 were sensitized with mite allergic patients' serum IgE in a 
final dilution of 1:30 o/n at 37°C. Degranulation of the cells was induced by adding 
nDer p 1, rDer p 2, rDer p 10 (100 ng/ml, 10 ng/ml, 1 ng/ml and 0.1 ng/ml) or buffer 
as control and assessed by measuring the ?-hexosaminidase release. Results are 
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reported as percentage of total ?-hexosaminidase release, where values obtained 
with buffer instead of allergen were subtracted. 
 
Statistical analysis 
Statistical significant differences of the allergen-specific IgE-reactivity 
frequencies in the Der p 10-positive and negative patients were analyzed using the 
multiple chi-square testing. The Mann-Whitney U test was applied to determine 
statistically significant differences regarding the induction of basophil degranulation 
with the different allergens. The p-values were adjusted using the Bonferroni-Holm 
correction. Differences were considered statistically significant if the p-value was 
lower than 0.05. 
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Results 
Expression and purification of folded rDer p 10 
The cDNA coding for Der p 10, which was obtained by RT-PCR from D. 
pteronyssinus RNA, was completely identical to the earlier described nucleotide 
sequence of Der p 10 (AF016278). The cDNA coding for the Der p 10 protein was 
subcloned into expression plasmid pET17b and was expressed as a soluble non-
fusion protein in E. coli BL21 (DE3). Between 3 - 7 mg of recombinant protein/liter of 
bacterial culture was purified by hydrophobic interaction and ion exchange 
chromatography to homogeneity (Fig. 1, A). In SDS-PAGE (Fig. 1, A) rDer p 10 
migrated at a molecular mass (i.e. 36 kDa) which was greater than that calculated 
from the amino acid sequence (32.972 kDa). However, MALDI-Tof mass 
spectrometry confirmed the calculated mass (32.939 kDa) (Fig. 1, B). The far UV-CD 
spectrum of purified recombinant Der p 10 recorded at 25°C showed two minima at 
209 and 221.5 nm and a large maximum at 191 nm, which is characteristic for a 
protein with predominantly ?-helical structure (Fig. 2, A). Calculation of the secondary 
structure using the program CDSSTR with the reference data set 7 resulted in 92% 
?-helix, 2% ?-sheets, 4% turns and 2% random-coils with an excellent fit between the 
calculated and measured spectrum (normalized root mean square difference value = 
0.004). A melting temperature, defined as midpoint of transition, of 44°C was 
determined at 222 nm (data not shown). Total unfolding of rDer p 10 occurred at 
50°C. However, even after heating to 95°C, the protein regained almost completely 
its fold after cooling to 25°C (Fig. 2, B). 
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rDer p 10 is immunologically equivalent to nDer p 10 and reacts with IgE from 
15% of house dust mite allergic patients 
To investigate whether rDer p 10 contains the IgE-epitopes of the natural Der p 
10, IgE inhibition experiments were performed. As exemplified in Fig. 3, 
preincubation of HDM allergic patients' sera with rDer p 10 completely inhibited IgE 
binding to nDer p 10, as well as to rDer p 10 but not to other HDM allergens (Fig. 3). 
Der p 10 was then used to search for specific IgE antibodies in 1322 sera from 
D. pteronyssinus allergic patients. These patients were typical HDM-allergic suffering 
from respiratory symptoms to HDM. We found that 201 (15.2%) of the patients had 
specific IgE antibodies to rDer p 10 (data not shown). 
 
rDer p 10-reactive patients are more often sensitized to HDM allergens other 
than Der p 1 and Der p 2 
A detailed analysis of the IgE reactivity profiles to other HDM allergens was 
performed in 39 of the 201 Der p 10-positive sera where sufficient serum was 
available. For comparison, 31 sera from the Der p 10-negative patients were 
randomly picked and analysed. Fig. 4 shows the frequency of IgE reactivity to nDer p 
1, rDer p 2, rDer p 5, rDer p 7 and rDer p 21 in the two groups. Table E1 displays a 
comparison of the intensities of IgE reactivity to the individual HDM allergens 
obtained by screening of the autoradiographies of the dot blots. 
Comparing the frequencies of IgE reactivity to the indicated HDM allergens in 
the Der p 10-positive and negative group, we observed striking differences regarding 
the reactivity profiles. More than 50% of the Der p 10-positive sera reacted with at 
least 5 of the tested HDM allergens (Fig. 4, Table E1). Twelve patients showed IgE 
reactivity to all 6 tested HDM allergens (30.8%) and nine reacted with 5 allergens 
(23.1%). The frequencies of IgE reactivities of rDer p 5 (p = 0.002), rDer p 7 (p = 
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0.024) and rDer p 21 (p = 0.005) were approximately 4 fold higher in the Der p 10 
positive compared to the Der p 10 negative patients (Fig. 4). By contrast, the majority 
of the Der p 10 negative sera (77.5 %) were characterized by a sensitization to 1 - 2 
HDM allergens (Table E1). Interestingly, five patients showed IgE reactivity only to 
Der p 10 but to none of the other HDM allergens (Table 1). 
 
Der p 10 has low allergenic activity in the majority of sensitized patients but 
can induce strong basophil degranulation in certain patients 
In order to study the allergenic activity of recombinant Der p 10, mediator 
release assays with an RBL cell line that had been transfected with the human Fc?RI 
receptor, were performed. RBL cells, loaded with serum IgE from the 39 Der p 10 
positive patients, were exposed to different concentrations of nDer p 1, rDer p 2 and 
rDer p 10. The mediator release at the allergen concentration (i.e. 100 ng/ml) giving 
the strongest basophil degranulation, is displayed in Fig. 5 and suppl. Table 1. In the 
majority of the patients, rDer p 10 induced weak or no basophil degranulation. 
Relevant degranulation upon exposure with rDer p 10 was however obtained with 4 
sera which were derived from patients who had also strong IgE reactivity to Der p 10 
(Fig. 5, suppl. Table 1). A relevant mediator release was observed for 22 (73.3%) and 
20 (64.5%) sera with nDer p 1 and rDer p 2, respectively, indicating that these 
allergens have much higher allergenic activity than Der p 10. 
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Discussion 
Tropomyosins are important food allergens which can cause severe 
anaphylactic reactions in sensitized patients.11 They show extensive cross-reactivity 
with mite tropomyosins but their relevance in house dust mite allergy has not been 
studied in detail. In order to investigate the importance of mite tropomyosin in HDM 
allergy, we expressed and purified rDer p 10, the tropomyosin from the mite D. 
pteronyssinus as authentic and folded protein which equals natural Der p 10 in terms 
of IgE reactivity. The reported prevalences of IgE recognition of mite tropomyosins in 
HDM patients showed a large variability from 5-80%.12, 13 In a population of more 
than 1300 HDM allergic patients we found that Der p 10 is recognized by 15.2% 
patients. 
When we performed an in depth analysis of sera from Der p 10-positive and 
negative patients regarding IgE reactivity to 5 other HDM allergens (nDer p 1, rDer p 
2, rDer p 5, rDer p 7 and rDer p 21) striking differences of IgE reactivity profiles 
between these two groups were noted. The majority of the Der p 10-positive patients 
was polysensitized to most of the tested allergens and certain patients showed strong 
and exclusive IgE reactivity to Der p 10. By contrast, the majority of Der p 10-
negative patients reacted only with Der p 1 and/or Der p 2 but not with the other HDM 
allergens. Our finding may have important clinical implications for HDM-specific 
immunotherapy. In fact, at present HDM extracts are only tested for the presence of 
Der p 1 and Der p 2 so that no information can be given by allergen extract 
manufacturers regarding the contents of allergens other than Der p 1 and Der p 2 in 
their extracts.25 Furthermore, it has been demonstrated that allergens other than Der 
p 1 and Der p 2 are missing in most of the commercially available allergen extracts.26 
(Casset & Vrtala, unpublished data). Based on our results it is very likely that patients 
Manuscript 1 
 50
from the Der p 10-positive group who are also sensitized against clinically highly 
relevant allergens such as Der p 5, Der p 7, Der p 21 may not benefit from HDM-
specific immunotherapy as well as patients who are primarily sensitized to Der p 1 
and Der p 2. 
The clinical relevance of Der p 10 among HDM allergic patients seems to be 
rather low compared to patients with food allergy to tropomyosin because only 
relatively few HDM allergic patients were sensitized to Der p 10, their IgE reactivities 
were rather weak and also the allergenic activity of Der p 10 was very low compared 
to that of Der p 1 and Der p 2. However, for a few patients Der p 10 appeared to be 
the only and most important HDM allergen which also exhibited high allergenic 
activity in the basophil degranulation assay.  
One possible explanation for the low frequency of sensitization, the low IgE 
reactivity and allergenic activity of Der p 10 may be that the allergen is not well 
represented in the respirable mite feces compared to other HDM allergens (e.g., Der 
p 1, Der p 2, Der p 5, Der p 7 and Der p 21)27, 28 but only occurs in the possibly less 
immunogenic dead mite body particles.29 
In conclusion, Der p 10 seems to be relevant only for a few HDM allergic 
patients. However, it allows identification of a subset of HDM allergic patients with a 
broad sensitization to HDM allergens other than Der p 1 and Der p 2 which may have 
important implications for the prescription of HDM-specific immunotherapy. 
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Figure legends 
Figure 1. Biochemical characterization of rDer p 10. (A) Coomassie Blue-stained 
SDS-PAGE. Molecular weight marker (lane M), 3 µg of purified rDer p 10 (lane rDer p 
10). (B) MALDI-Tof analysis of rDer p 10. The x-axis shows the mass/charge ratio. 
Signal intensities as percentage of the most abundant signal (y-axis). 
 
Figure 2. CD analysis of rDer p 10. The molecular ellipticities [?] (y-axes) at different 
wavelengths (x-axes) are displayed for different temperatures (A), (B) CD spectra of 
the protein at 25°C and refolding after heating to 95°C and cooling down to 25°C. 
 
Figure 3. Inhibition of IgE reactivity to blotted nDer p 10 by rDer p 10. Nitrocellulose-
blotted D. pteronyssinus extract (left panels) or rDer p 10 (right panels) were 
incubated with sera from Der p 10-sensitized patients (A12 and A30), which had 
been pre-incubated with (+) or without (-) rDer p 10. Molecular weights (kDa) were 
shown at the margins.  
 
Figure 4. Frequencies (% of reactive sera) of IgE recognition (y-axis) of HDM 
allergens (x-axis) are shown for HDM allergic patients with (grey bars) or without 
(white bars) IgE antibodies to rDer p 10. Statistically significant differences between 
the two groups are indicated (* p < 0.05). 
 
Figure 5. Allergenic activity of nDer p 1, rDer p 2 and rDer p 10. RBL cells were 
loaded with IgE from Der p 10-sensitized patients and degranulation was induced 
with nDer p 1, rDer p 2 or rDer p 10 (x-axis). The intensities of basophil degranulation 
are shown as percentages of total ?-hexosaminidase release (y-axis) as a scatter 
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plot. Median mediator release values and the cutoff (5% mediator release) are 
indicated by a horizontal black and dashed line, respectively. Statistically significant 
differences are indicated (* p < 0.05). 
 
Supplemental Figure E1. Quantification of the IgE reactivity intensities to the 
individual HDM allergens using the image analysis software Image J exemplified on 
patient A39. (A) A grey-scaled, background-subtracted and inverted image of the 
autoradiography film was prepared before the individual dots were outlined (see 
yellow circles). (B) “Area” value (area of selection in square pixels) and “mean grey 
value” (sum of the grey values of all the pixels in the selection divided by the number 
of pixels) were measured by the program and multiplied resulting in the “integrated 
density” value (IntDen). 
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Der p 10-positive sera
Patient nDer p 1 rDer p 2 rDer p 5 rDer p 7 rDer p 10 rDer p 21 nDer p 1 rDer p 2 rDer p 10
A1 26.88 38.12 32.74 - 0.93 38.37 0.46 5.27 2.12
A2 20.49 87.13 - - 43.52 - 12.94 5.42 2.46
A3 3.53 55.61 85.44 29.21 13.75 - 4.83 9.17 2.67
A4 2.02 49.94 - - 75.58 - 0.00 4.50 5.31
A5 53.32 106.55 121.13 50.44 1.16 89.29 19.13 17.21 0.71
A6 24.61 118.27 147.50 77.63 1.52 137.09 36.73 28.67 4.66
A7 6.44 95.26 98.91 - 2.10 - 17.68 19.00 2.55
A8 - 1.61 - - 14.37 - - 0.78 2.81
A9 2.05 82.39 147.08 - 1.03 1.09 31.88 33.66 3.00
A10 - - 111.59 13.37 1.27 59.33 - - 1.73
A11 59.02 139.14 3.47 - 0.82 70.80 45.13 42.86 2.78
A12 1.29 37.64 24.81 22.64 5.41 1.67 1.74 10.93 3.85
A13 - - - - 98.74 - - - 22.03
A14 15.48 39.95 86.25 20.30 57.43 2.13 13.41 16.84 7.47
A15 48.43 124.23 - - 1.00 - 45.19 47.49 3.54
A16 43.06 102.55 69.23 27.53 34.90 1.15 60.44 42.05 3.80
A17 35.40 109.79 72.35 39.38 1.34 1.15 35.50 38.52 4.85
A18 12.02 79.89 68.91 61.67 1.33 56.68 4.39 26.51 4.68
A19 2.14 86.38 114.72 - 1.24 2.09 28.04 44.49 4.75
A20 18.24 97.29 84.69 105.90 6.65 - 47.25 41.42 6.25
A21 30.62 83.58 21.13 - 1.55 20.84 31.66 33.41 5.27
A22 23.66 - - - 22.05 - 34.82 - 5.02
A23 25.34 77.88 107.98 35.52 1.34 105.71 19.68 27.88 5.48
A24 34.25 12.33 4.73 - 185.50 - 34.62 1.88 31.10
A25 44.06 93.34 62.71 42.89 1.26 12.37 48.10 37.67 2.86
A26 - - - - 1.20 - - - 3.05
A27 23.73 101.69 86.08 41.17 1.94 119.62 22.66 33.71 1.60
A28 - 1.06 - - 38.31 - - 0.00 2.65
A29 1.98 - - - 56.64 - 1.23 - 7.10
A30 - - - - 41.67 - - - 2.36
A31 24.18 137.17 - - 27.42 - 39.62 36.04 3.99
A32 10.22 92.03 70.37 1.06 37.88 6.14 13.87 1.67 1.95
A33 2.99 72.09 90.96 - 34.02 49.48 3.61 1.95 1.95
A34 0.92 29.48 - - 1.08 - 1.13 2.00 3.03
A35 - 36.32 - - 4.25 - - 2.03 0.43
A36 - - - - 15.45 - - - 1.85
A37 - - - - 172.09 - - - 22.25
A38 33.43 99.57 60.15 - 1.15 66.85 18.24 11.50 0.44
A39 32.28 127.55 132.97 10.78 84.01 73.55 42.18 29.92 11.87
Der p 10-negative sera
Patient nDer p 1 rDer p 2 rDer p 5 rDer p 7 rDer p 10 rDer p 21
B1 13.52 34.87 - - - -
B2 35.49 103.83 - - - -
B3 - 4.37 - - - -
B4 64.14 90.53 - 55.40 - -
B5 3.16 19.63 - - - -
B6 - 59.10 - - - -
B7 1.24 28.23 - - -
B8 10.53 36.84 0.90 - - -
B9 17.14 45.25 - - - -
B10 5.90 17.78 - 1.73 - -
B11 2.95 - - - - -
B12 - 29.06 - - - -
B13 1.86 19.01 - - - -
B14 4.29 - - - - -
B15 - 54.86 - - - -
B16 1.06 - - - - 16.35
B17 6.20 74.17 55.33 - - - Integrated 
B18 7.90 47.55 - - - - density
B19 21.81 52.59 - - - - x 10
4
B20 37.48 46.58 - - - - 0 - 15
B21 21.72 35.13 85.03 7.80 - 44.97 15.01 - 60
B22 28.90 38.51 - - - - 60.01-185.50
B23 - 37.34 - - - -
B24 42.95 76.78 - - - - percentage
B25 1.39 33.17 - - - - of total
B26 - 13.78 0.75 - - 15.52  ?-hexos-
B27 - 3.28 - - - - aminidase
B28 2.32 - - - - -  release
B29 - 19.55 - - - - 0 - 5
B30 3.43 3.86 - - - - 5.01 - 10
B31 41.59 53.93 106.56 - - 57.90 10.01 - 60.44
?-hexosaminidase releaseIntegrated density (x 10
4
)
Table E1. Allergen specific IgE reactivity and basophil degranulation measured for sera from 
Der p 10-positive and negative HDM allergic patients
IgE reactivity Basophil degranulation
Percentage of total
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Type I hypersensitivity, better known as allergy, represents a major health 
problem in industrialized countries, with more than 20% of the population being 
affected. House dust mites (HDM) are among the most important elicitors of Type I 
allergy, with a prevalence of sensitization of more than 50% among allergic patients. 
The introduction of recombinant DNA technology into the field of allergy 
represents an important step towards the improvement of diagnosis and treatment of 
allergic patients. Allergen extracts that are nowadays in use, are difficult to 
standardize, certain important allergens are under-represented or the extracts may 
be contaminated with allergens from other sources or bacterial endotoxins. Thus, 
they may fail in diagnosis or induce unwanted side-effects in immunotherapy. The 
use of pure and defined recombinant allergens might overcome these problems. The 
successful diagnosis and immunotherapy of HDM-allergic patients with recombinant 
allergens requires a panel of all important allergens that induce relevant symptoms in 
patients. IgE-binding frequency, allergen-specific IgE level and in particular the 
allergenic activity have to be taken in consideration when deciding about the 
importance of an allergen. 
The major aim of this thesis was to evaluate the relevance of the house dust 
mite tropomyosin, Der p 10, in HDM allergic patients. A recombinant protein was 
produced in a bacterial expression system that equals its natural counterpart 
regarding biochemical, structural and immunological properties. Der p 10 showed low 
IgE reactivity (15.2%) and low allergenic activity in the vast majority of the tested Der 
p 10-positive HDM-allergic patients, which indicates a rather low clinical relevance of 
the mite tropomyosin in HDM allergic patients. Nevertheless, our results revealed that 
Der p 10-positive and negative patients showed substantial differences regarding 
their sensitization profiles to HDM allergens which has implications for specific 
immunotherapy treatment. 
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Chapter III describes a case report of a 55-year-old woman who developed an 
anaphylactic shock after drinking a TCM (traditional Chinese medicine) tea. As the 
individual components of the tea failed to cause a positive reaction in skin prick tests, 
a contamination of the tea was assumed. Our results excluded house dust mites and 
storage mites from being the contaminating source and identified silk allergens 
probably derived from insect pests as being the reaction-causing source. 
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Typ I Hypersensitivität, besser bekannt als Allergie, stellt ein bedeutendes 
Gesundheitsproblem in industrialisierten Ländern dar, von dem mehr als 20% der 
Bevölkerung betroffen ist. Hausstaubmilben zählen zu den wichtigsten Auslösern der 
Typ I Allergie, mit einer Sensibilisierungsprävalenz von mehr als 50% unter 
Allergikern. 
Die Einführung der rekombinanten DNA Technologie in den Bereich der Allergie 
stellt einen wichtigen Schritt in Richtung Verbesserung von Diagnose und Therapie 
von allergischen Patienten dar. Allergenextrakte, die heutzutage verwendet werden, 
sind schwierig zu standardisieren, einige wichtige Allergene sind unterrepräsentiert, 
oder die Extrakte sind mit Allergenen anderer Quellen oder bakteriellen Toxinen 
kontaminiert. Diese können daher ein falsch negatives Diagnoseergebnis und 
unerwünschte Nebenwirkungen in der Immuntherapie verursachen. Die Verwendung 
von reinen und definierten rekombinanten Allergenen könnte diese Probleme 
beseitigen. Eine erfolgreiche Diagnose und Immuntherapie von Hausstaubmilben-
allergikern mit rekombinanten Allergenen benötigt die Summe aller wichtigen 
Allergene, die relevante Symptome in Patienten hervorrufen. Die IgE-Bindungs-
frequenz, der allergenspezifische IgE-Spiegel und im Speziellen die allergene 
Aktivität müssen in Betracht gezogen werden wenn über die Wichtigkeit eines 
Allergens entschieden werden soll. 
Das Hauptziel dieser Diplomarbeit war es, die Relevanz des Hausstaub-
milbentropomyosins, Der p 10, in Milbenallergikern zu untersuchen. Es wurde ein 
rekombinantes Protein in einem bakteriellen Expressionssystem produziert, dass 
seinem natürlichen Gegenstück in biochemischer, struktureller und immunologischer 
Hinsicht glich. Der p 10 zeigte eine niedrige IgE-Reaktivität (15.2%), sowie eine 
schwache allergene Aktivität in der Mehrheit der getesteten Der p 10 positiven 
Hausstaubmilbenallergikern, was auf eine eher niedrige klinische Relevanz des 
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Milbentropomyosins hindeutet. Unsere Ergebnisse zeigten allerdings, dass sich Der 
p 10 positive und negative Patienten beachtlich in ihrem Hausstaubmilben-
sensibilisierungsprofil unterscheiden. Dies könnte Auswirkungen auf eine spezifische 
Immuntherapiebehandlung haben. 
Kapitel III beschreibt den Fallbericht einer 55-jährigen Frau, die nach Konsum 
eines TCM- (traditionelle chinesische Medizin) Tees einen anaphylaktischen Schock 
erlitt. Da die Einzelkomponenten des Tees keine positive Reaktion im Pricktest 
verursachten, wurde eine Kontamination des Tees vermutet. Unsere Ergebnisse 
schlossen eine Verunreinigung mit Hausstaub- und Vorratsmilben aus. Im Folgenden 
konnte eine Kontamination mit Seidenproteinen, die wahrscheinlich von 
Lebensmittelmotten stammen, gezeigt werden. Diese scheinen für die starke 
allergische Reaktion verantwortlich zu sein. 
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